Written by Healing Sky Editorial Team. Clinically reviewed by Cynthia Abraham D.O.
Relapse prevention is rarely about willpower alone. The strongest recovery plans blend therapy, structure, social support, and, when appropriate, medication. While the FDA has approved medications for opioid and alcohol use disorders, there are no approved anti‑craving medications for many other drugs. In day‑to‑day practice, psychiatrists often use off‑label medication‑assisted therapies to reduce cravings, stabilize mood and sleep, and make recovery more durable. Used carefully, these medicines can shift recovery from white‑knuckling to real momentum.
This guide explains the most effective off‑label options for relapse prevention from substances other than opioids and alcohol. It is written for people in recovery, their families, and clinicians who want a clear, high‑level map of what actually helps. Nothing here replaces medical advice; off‑label prescribing always requires a personalized evaluation, informed consent, and close follow‑up.
"Off‑label" means using an approved medication for a condition it was not formally approved to treat, based on clinical judgment and the best available evidence. In addiction psychiatry, this is common because research and regulatory approval have lagged urgent need. A medicine that modestly decreases cravings or shortens binges can produce real gains when layered onto therapy and recovery supports. Even small improvements, such as better sleep, less withdrawal‑related anxiety, or more emotional steadiness, can translate into fewer high‑risk moments and longer stretches of sobriety.
Off‑label prescribing is not guesswork. It involves a clear treatment target (for example, reduce methamphetamine craving and improve sleep), informed consent about benefits, risks, and alternatives, monitoring for side effects and functional improvement, and a plan to stop or switch if the medication is not helping.
For cocaine or methamphetamine use disorder, several medications show benefit, especially when combined with therapy and contingency management. None is a silver bullet; each has a distinct profile that may match certain patients better than others.
Bupropion reduces cravings and days of use for some patients, particularly those with methamphetamine use disorder, co‑occurring depression, or nicotine dependence. Its activating profile can counter the low energy and anhedonia common in early recovery. It can increase anxiety or insomnia, however, and carries a seizure risk in susceptible individuals. It is not appropriate for people with certain eating disorders (for example, bulimia) or an uncontrolled seizure disorder.
Extended‑release naltrexone plus bupropion is a strategy worth noting for methamphetamine use disorder: a monthly extended‑release naltrexone injection paired with daily bupropion. In a large randomized trial, this combination produced a modest but statistically meaningful increase in response rates versus placebo, appearing to curb craving and reduce reinforcement. It requires being opioid‑free before starting naltrexone and is not suitable for patients who rely on opioid pain medicines. Side effects can include nausea and headache, and access, cost, and logistics are real considerations.
Mirtazapine can reduce methamphetamine use in some groups, especially when insomnia, appetite loss, or anxiety dominate the clinical picture. It improves sleep architecture, which is often a turning point in stimulant recovery. Daytime sedation and weight gain can occur; paradoxical activation is uncommon but possible.
Topiramate may reduce heavy cocaine use and promote longer abstinence intervals. It is also useful when migraines or weight concerns are present. Cognitive side effects (word‑finding difficulty, slowed thinking), paresthesias, and taste changes can limit use, and it is unsafe in pregnancy due to teratogenic risk.
Modafinil, a wake‑promoting agent, may reduce cocaine craving for some patients, particularly those with daytime sleepiness. Data are mixed, so it is used selectively. It can cause insomnia, anxiety, or headaches, and drug interactions and rare skin reactions must be considered.
Long‑acting prescription stimulants are appropriate for patients with confirmed ADHD. Treating ADHD with long‑acting methylphenidate or amphetamine formulations can reduce illicit stimulant use, improve function, and cut relapse risk. The goal is stabilization, not euphoria. Diversion and misuse risk require safeguards: daily routines, limited quantities, Prescription Drug Monitoring Program checks, random pill counts, and urine drug screens.
The choice among these options follows the patient's clinical picture. Bupropion fits best when co‑occurring depression, nicotine dependence, or low energy are prominent. The naltrexone plus bupropion combination suits methamphetamine use with significant craving when the patient can commit to monthly injections and has no current opioid use. Mirtazapine is the better choice when insomnia, appetite loss, and anxiety are the dominant complaints. Topiramate is worth considering for cocaine use with a migraine history or weight concerns, provided the patient has high motivation to tolerate a slow titration. Modafinil fits patients with daytime sleepiness or irregular schedules who need to stay alert without euphoria. Stimulant medications are reserved for confirmed ADHD within a structured monitoring plan.
There is no FDA‑approved anti‑craving medication for cannabis use disorder, but several off‑label options help particular patients, most often by easing withdrawal symptoms such as disrupted sleep, irritability, and anxiety, and by blunting cue‑driven use. The choice depends on symptoms, age, comorbidities, and tolerability.
Gabapentin reduces withdrawal‑related anxiety, irritability, and insomnia; some patients also report fewer days of use. It is often well tolerated and familiar to many clinicians. Dizziness or fatigue can occur, and misuse, while uncommon in most patients, is not zero, so monitoring is warranted, especially in people with polysubstance use.
N‑acetylcysteine (NAC) is an over‑the‑counter supplement that may reduce cannabis use in adolescents and young adults. It is safe and inexpensive, making it a reasonable first step for families seeking a lower‑risk option. Adult data are mixed, and effects, when present, are usually modest. Gastrointestinal upset is possible.
Topiramate can reduce the amount used and frequency, particularly in heavier users, and may also help with weight and migraines. Cognitive side effects are more common at higher doses, so a slow titration is important. It should be avoided during pregnancy.
Prescription‑grade cannabidiol (CBD) at high doses has shown signals for reducing cannabis use and withdrawal in some studies. It is non‑intoxicating. Cost and access can be barriers, and potential interactions with liver‑metabolized drugs require monitoring. Over‑the‑counter CBD products are unregulated and unreliable in dose, and are not a substitute.
Short‑term nonaddictive sleep aids, such as trazodone or low‑dose doxepin, can bridge the first month when insomnia is driving relapse. These do not treat craving directly; they are best used as brief, targeted supports while therapy builds coping skills.
Among these options, gabapentin fits best when anxiety and insomnia are the primary complaints during early abstinence. NAC is a reasonable starting point for adolescent or college‑age patients with engaged family support. Topiramate suits heavy daily use with high motivation and room for slow titration. Prescription CBD is appropriate when there is a strong preference to avoid psychoactive effects and willingness to pursue a monitored pharmaceutical product.
Benzodiazepine and Z‑drug (zolpidem, eszopiclone) use disorder presents a different challenge. There is no reliable anti‑craving medication for these substances. Relapse prevention hinges on the mechanics of a safe taper, insomnia and anxiety treatment that avoids addictive reinforcement, and intensive behavioral care.
A gradual, individualized taper plan using longer‑acting agents when needed forms the foundation. CBT for insomnia (CBT‑I) and CBT for anxiety address the conditions that most commonly drive return to sedative use. Nonaddictive anxiety supports, including SSRIs, SNRIs, buspirone, and hydroxyzine, can be tailored to the underlying diagnosis. Two approaches to avoid: substituting with gabapentinoids or barbiturates long‑term, as both carry misuse potential and do not reliably prevent relapse; and prescribing as‑needed benzodiazepines after a taper, since PRN dosing almost always fuels a cycle of relief and rebound anxiety. When persistent generalized anxiety, panic, PTSD, or depression would otherwise push someone back toward sedatives, treating that underlying condition directly is the priority.
Evidence is thin across this category, but a few principles guide care.
For GHB (gamma‑hydroxybutyrate) use disorder, baclofen, a GABA‑B agonist, can reduce cravings in some patients based on small studies and case series. Sedation, dizziness, and interactions with other CNS depressants require strict precautions, and this is a subspecialty decision requiring close monitoring.
For ketamine misuse, no established medication prevents relapse. Behavioral therapies, safety planning, and addressing co‑occurring depression or trauma drive outcomes. Sleep stabilization and structured schedules can reduce nighttime triggers, when ketamine use most often occurs.
For MDMA (ecstasy) misuse, no proven anti‑craving medication exists. The focus is on CBT and contingency management, along with addressing the needs MDMA was meeting, such as connection, mood lift, and novelty, through healthier alternatives.
For inhalant use disorder and for classic hallucinogens (LSD, psilocybin), medication‑assisted relapse prevention is not established. Safety education, therapy, and addressing environmental triggers are central. Persistent anxiety, depression, or psychosis should be treated directly to reduce relapse pressure.
The most effective off‑label medication is the one that targets a patient's specific relapse drivers while protecting their health. A thorough evaluation should consider several domains.
Treating true ADHD can sharply reduce stimulant relapse risk. Long‑acting stimulants may be appropriate with strict safeguards; non‑stimulants such as atomoxetine and guanfacine can also help attention and impulse control. Mood and anxiety disorders are equally important: bupropion, mirtazapine, SSRIs, or SNRIs can treat the disorder and reduce drug‑seeking triggered by low mood, sleep loss, or panic. Untreated insomnia is one of the strongest relapse predictors across substances, making nonaddictive sleep supports and CBT‑I high‑priority interventions. Pain syndromes require coordinated care, since opioids are off the table when naltrexone is part of the plan, and non‑opioid strategies and functional restoration become more important.
Medical conditions also constrain choices: pregnancy rules out topiramate; seizure risk rules out bupropion; liver disease calls for caution with multiple agents; and HIV medications require interaction checks. Age and setting matter as well. Adolescents benefit from family involvement and school coordination, while adults may need workplace accommodations or medical leave to stabilize early recovery.
Shared decision‑making is the rule. The process starts with the patient's goals and the patterns of their use: when cravings spike, which feelings or cues trigger use, and where previous attempts broke down. From there, the simplest, safest medication that aligns with those targets is chosen.
Medication is an accelerator, not the engine. The strongest evidence for reducing stimulant and cannabis use comes from behavioral treatments, and these should run alongside any medication trial.
Contingency management uses structured incentives for negative drug screens and recovery activities. It is one of the most powerful tools available, especially for stimulants. Cognitive behavioral therapy builds skills for craving surfing, trigger mapping, and restructuring thoughts that nudge use. Community reinforcement approach builds a life that is more rewarding than the drug, through activities, relationships, employment, and health. Motivational interviewing deepens commitment to change and makes ambivalence explicit so it can be worked with rather than around. Peer groups, family involvement, and sober housing round out the support structure when needed.
These therapies increase motivation, coping capacity, and reinforcement for sobriety, so even modest medication effects translate into behavior change.
Before starting any off‑label relapse prevention medication, a practical safety review should cover the following:
A successful medication trial should tilt daily life in a measurable direction. Fewer days of use and longer gaps between episodes are the clearest signals. Cravings that feel more like background noise than urgent commands indicate the medication is working. Shorter binges and faster recovery afterward, better sleep, a more stable mood, re‑engagement with work, school, or family roles, and fewer medical or legal crises all reflect a plan that is working. If those gains do not appear within a reasonable trial period, the plan should change.
Because this article focuses on substances other than opioids and alcohol, it does not cover medications primarily used for those disorders, such as buprenorphine, methadone, acamprosate, or disulfiram. For nicotine, several FDA‑approved options exist, including varenicline, bupropion SR, and nicotine replacement, so off‑label strategies are rarely needed. If tobacco is part of the recovery picture, addressing it directly is worthwhile because quitting nicotine often improves outcomes for other substances.
Off‑label medication‑assisted therapy is not a last resort; for many people, it is an evidence‑informed way to make relapse less likely and recovery more livable. The goal is matching the medicine to a patient's relapse triggers, health profile, and life circumstances.
If you or a loved one is navigating recovery from cocaine, methamphetamine, cannabis, benzodiazepines, or club drugs, Healing Sky can help build a plan that works in the real world. Working with a board‑certified psychiatrist, you will:
If you are ready to explore whether an off‑label medication could support your relapse prevention plan, reach out to schedule a consultation. If you are in immediate distress or worried about your safety, call or text 988 for the Suicide & Crisis Lifeline, or seek emergency care.
Medically reviewed by Cynthia Abraham, D.O.
Read More
(NA)
Read More
(NA)
Read More
(NA)
Sign up now to get unrestricted access to Healing Sky's online mental health directory, resources, and more!
Sign up now
